Aerie Pharmaceuticals: New Perspectives on Dry Eye Disease – Current Landscape, Unmet Needs and Emerging Treatment Options
|DATE:||September 23, 2022|
|TIME:||10:00 AM EDT|
About The Event
Join us for an Aerie Pharmaceuticals Key Opinion Leader event featuring subject-matter experts Laura Periman, MD (Periman Eye Institute) and John Sheppard, MD (Virginia Eye Consultants) who will discuss the current dry eye landscape with a focus on unmet needs and emerging advances in treatment options, including Aerie’s investigational TRPM8 agonist, AR-15512.
AR-15512 is currently in registrational Phase 3 trials for the treatment of dry eye disease. Aerie’s leadership team will provide a brief overview of AR-15512 and an update on the Phase 3 clinical development program. A live question and answer session will follow.